<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01407471</url>
  </required_header>
  <id_info>
    <org_study_id>P071011</org_study_id>
    <nct_id>NCT01407471</nct_id>
  </id_info>
  <brief_title>Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy</brief_title>
  <acronym>SPIREPI</acronym>
  <official_title>Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Société de Dermatologie Française</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether spironolactone could significantly reduce
      cutaneous atrophy due to corticosteroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      skin cutaneous atrophy due to corticosteroids limits the long-term use of highly potent
      topical glucocorticoids which are the treatment of choice for many inflammatory skin
      diseases. This atrophy results in fragile skin, delay of healing, purpura, irreversible
      striae, telangiectasia and secondary infections. Up to now, no treatments can prevent
      efficiently skin atrophy.

      The mineralocorticoid receptor, belonging to the superfamily of nuclear receptors, is
      expressed in human epidermis but its actual function is unknown. Experimental results in
      animals obtained in INSERM unit U772 by Dr N FARMAN suggest that spironolactone which is a
      mineralocorticoid receptor antagonist 1- might limit epidermal atrophy and 2- might promote
      healing.

      Study description We propose to test clinically these hypotheses for the first time on
      humans, at the CIC in BICHAT's hospital on healthy volunteers: 1- by applying on the skin a
      highly potent cutaneous corticosteroids in association or not with spironolactone, 2- by
      applying or not spironolactone on wounds after 3-mm punch biopsies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>histological measure of epidermal thickness</measure>
    <time_frame>day 29</time_frame>
    <description>biopsies will be performed in the center of the treated sites. Epidermal thickness will be measured from the basal lamina to the lower border of the stratum corneum. This will be determined by image analysis from the average of fields per skin section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>delay of healing after skin biopsies performed on day 29</measure>
    <time_frame>days 32, 36, 39, 43, 46, 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermis thickness evaluated by ultrasound</measure>
    <time_frame>days 1, 15, 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mineral receptors and glucoreceptors expression ratio performed by immunohistochemistry</measure>
    <time_frame>day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Cutaneous Atrophy Due to Corticosteroids</condition>
  <arm_group>
    <arm_group_label>Clobetasol + Spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.05% clobetasol and 5% spironolactone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clobetasol + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.05% clobetasol + inert excipient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inert excipient + 5% spironolactone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inert excipient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobetasol + Spironolactone</intervention_name>
    <description>One application 6 days a week during 4 weeks</description>
    <arm_group_label>Clobetasol + Spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobetasol + Placebo</intervention_name>
    <description>One application 6 days a week during 4 weeks</description>
    <arm_group_label>Clobetasol + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Spironolactone</intervention_name>
    <description>One application 6 days a week during 7 weeks</description>
    <arm_group_label>Placebo + Spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Placebo</intervention_name>
    <description>One application 6 days a week during 7 weeks</description>
    <arm_group_label>Placebo + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers of both sex, aged between 20 and 50 years

          -  Woman with effective contraception and pregnancy test negative before inclusion.

          -  Subject considered healthy after a detailed review (interview, clinical examination)

          -  Subject belonging to a social security scheme (beneficiary or have the right)

          -  Subject having signed a free and informed consent

          -  Integrity of the skin at forearms

          -  Subject available the next 7 weeks and able to go to CIC once a day from Monday to
             Friday

          -  Subject accepting four skin biopsies at D29

          -  no washing forearms during 2 hours after applications

        Exclusion Criteria:

          -  Chronic Alcoholism

          -  Drug-addiction (comprehensive interview with a sampling in case of doubt)

          -  Woman pregnant or breast-feeding

          -  Subject involved in another trial or in exclusion period of another protocol

          -  Subject has already received more than 3700 Euros in compensation for damages suffered
             constraints in the past 12 months for his involvement in biomedical researches

          -  Subject has already participated in this protocol

          -  Phototypes 5 and 6

          -  Clinical skin atrophy

          -  History of severe chronic skin disease

          -  Problems of healing

          -  Treatment with oral corticosteroids, mineralocorticoids or spironolactone (Aldactone,
             Flumach, Practon, Spiroctan, Spironone, Aldactazine, ALDALIX, Practazin, Spiroctazine
             ...)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eve MAUBEC, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bichat Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Farman N, Maubec E, Poeggeler B, Klatte JE, Jaisser F, Paus R. The mineralocorticoid receptor as a novel player in skin biology: beyond the renal horizon? Exp Dermatol. 2010 Feb;19(2):100-7. doi: 10.1111/j.1600-0625.2009.01011.x. Epub 2009 Nov 18. Review.</citation>
    <PMID>19925636</PMID>
  </reference>
  <reference>
    <citation>Bayo P, Sanchis A, Bravo A, Cascallana JL, Buder K, Tuckermann J, Schütz G, Pérez P. Glucocorticoid receptor is required for skin barrier competence. Endocrinology. 2008 Mar;149(3):1377-88. Epub 2007 Nov 26.</citation>
    <PMID>18039792</PMID>
  </reference>
  <reference>
    <citation>Sainte Marie Y, Toulon A, Paus R, Maubec E, Cherfa A, Grossin M, Descamps V, Clemessy M, Gasc JM, Peuchmaur M, Glick A, Farman N, Jaisser F. Targeted skin overexpression of the mineralocorticoid receptor in mice causes epidermal atrophy, premature skin barrier formation, eye abnormalities, and alopecia. Am J Pathol. 2007 Sep;171(3):846-60. Epub 2007 Aug 3.</citation>
    <PMID>17675581</PMID>
  </reference>
  <reference>
    <citation>Stojadinovic O, Lee B, Vouthounis C, Vukelic S, Pastar I, Blumenberg M, Brem H, Tomic-Canic M. Novel genomic effects of glucocorticoids in epidermal keratinocytes: inhibition of apoptosis, interferon-gamma pathway, and wound healing along with promotion of terminal differentiation. J Biol Chem. 2007 Feb 9;282(6):4021-34. Epub 2006 Nov 9.</citation>
    <PMID>17095510</PMID>
  </reference>
  <reference>
    <citation>Leyvraz C, Charles RP, Rubera I, Guitard M, Rotman S, Breiden B, Sandhoff K, Hummler E. The epidermal barrier function is dependent on the serine protease CAP1/Prss8. J Cell Biol. 2005 Aug 1;170(3):487-96.</citation>
    <PMID>16061697</PMID>
  </reference>
  <reference>
    <citation>List K, Haudenschild CC, Szabo R, Chen W, Wahl SM, Swaim W, Engelholm LH, Behrendt N, Bugge TH. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene. 2002 May 23;21(23):3765-79.</citation>
    <PMID>12032844</PMID>
  </reference>
  <reference>
    <citation>Mauro T, Guitard M, Behne M, Oda Y, Crumrine D, Komuves L, Rassner U, Elias PM, Hummler E. The ENaC channel is required for normal epidermal differentiation. J Invest Dermatol. 2002 Apr;118(4):589-94.</citation>
    <PMID>11918703</PMID>
  </reference>
  <reference>
    <citation>Pérez P, Page A, Bravo A, Del Río M, Giménez-Conti I, Budunova I, Slaga TJ, Jorcano JL. Altered skin development and impaired proliferative and inflammatory responses in transgenic mice overexpressing the glucocorticoid receptor. FASEB J. 2001 Sep;15(11):2030-2. Epub 2001 Jul 24.</citation>
    <PMID>11511512</PMID>
  </reference>
  <reference>
    <citation>Brouard M, Casado M, Djelidi S, Barrandon Y, Farman N. Epithelial sodium channel in human epidermal keratinocytes: expression of its subunits and relation to sodium transport and differentiation. J Cell Sci. 1999 Oct;112 ( Pt 19):3343-52.</citation>
    <PMID>10504339</PMID>
  </reference>
  <reference>
    <citation>Roudier-Pujol C, Rochat A, Escoubet B, Eugène E, Barrandon Y, Bonvalet JP, Farman N. Differential expression of epithelial sodium channel subunit mRNAs in rat skin. J Cell Sci. 1996 Feb;109 ( Pt 2):379-85.</citation>
    <PMID>8838661</PMID>
  </reference>
  <reference>
    <citation>Kenouch S, Lombes M, Delahaye F, Eugene E, Bonvalet JP, Farman N. Human skin as target for aldosterone: coexpression of mineralocorticoid receptors and 11 beta-hydroxysteroid dehydrogenase. J Clin Endocrinol Metab. 1994 Nov;79(5):1334-41.</citation>
    <PMID>7962326</PMID>
  </reference>
  <reference>
    <citation>Messina M, Manieri C, Musso MC, Pastorino R. Oral and topical spironolactone therapies in skin androgenization. Panminerva Med. 1990 Apr-Jun;32(2):49-55.</citation>
    <PMID>2147469</PMID>
  </reference>
  <reference>
    <citation>Maubec E, Laouénan C, Deschamps L, Nguyen VT, Scheer-Senyarich I, Wackenheim-Jacobs AC, Steff M, Duhamel S, Tubiana S, Brahimi N, Leclerc-Mercier S, Crickx B, Perret C, Aractingi S, Escoubet B, Duval X, Arnaud P, Jaisser F, Mentré F, Farman N. Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin. J Invest Dermatol. 2015 Jul;135(7):1781-1789. doi: 10.1038/jid.2015.44. Epub 2015 Feb 10.</citation>
    <PMID>25668238</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2011</study_first_submitted>
  <study_first_submitted_qc>August 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2011</study_first_posted>
  <last_update_submitted>July 2, 2015</last_update_submitted>
  <last_update_submitted_qc>July 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aldosterone</keyword>
  <keyword>clobetasol</keyword>
  <keyword>atrophy</keyword>
  <keyword>skin</keyword>
  <keyword>epidermis</keyword>
  <keyword>wound healing</keyword>
  <keyword>mineral corticoid receptor</keyword>
  <keyword>spironolactone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

